abstract |
The present invention treats a combination of a soluble guanylate cyclase stimulant (sGC stimulant) and a mineralocorticoid receptor antagonist (MR antagonist), as well as heart and cardiovascular disorders, kidney and cardiorenal disorders, lung and cardiopulmonary disorders, and It relates to the use of the combination for preventing and / or preventing and treating and / or preventing fibrotic disorders. |